CA3039485A1 - Antifungal dry powders - Google Patents
Antifungal dry powders Download PDFInfo
- Publication number
- CA3039485A1 CA3039485A1 CA3039485A CA3039485A CA3039485A1 CA 3039485 A1 CA3039485 A1 CA 3039485A1 CA 3039485 A CA3039485 A CA 3039485A CA 3039485 A CA3039485 A CA 3039485A CA 3039485 A1 CA3039485 A1 CA 3039485A1
- Authority
- CA
- Canada
- Prior art keywords
- dry powder
- dry
- itraconazole
- formulation
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408376P | 2016-10-14 | 2016-10-14 | |
| US62/408,376 | 2016-10-14 | ||
| PCT/US2017/056497 WO2018071757A1 (en) | 2016-10-14 | 2017-10-13 | Antifungal dry powders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3039485A1 true CA3039485A1 (en) | 2018-04-19 |
Family
ID=60186406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3039485A Pending CA3039485A1 (en) | 2016-10-14 | 2017-10-13 | Antifungal dry powders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11116722B2 (https=) |
| EP (1) | EP3525759A1 (https=) |
| JP (1) | JP7085538B2 (https=) |
| KR (1) | KR102408798B1 (https=) |
| CN (1) | CN109996536B (https=) |
| AU (1) | AU2017341815B2 (https=) |
| CA (1) | CA3039485A1 (https=) |
| IL (1) | IL265913B2 (https=) |
| MX (1) | MX388733B (https=) |
| NZ (1) | NZ752353A (https=) |
| RU (1) | RU2766086C2 (https=) |
| WO (1) | WO2018071757A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013007304B1 (pt) * | 2010-09-29 | 2021-12-14 | Pulmatrix, Inc. | Pós secos de cátion de metal monovalente para inalação |
| EP3781125A1 (en) * | 2018-04-18 | 2021-02-24 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
| CN112423755A (zh) * | 2018-04-18 | 2021-02-26 | 希普拉技术有限责任公司 | 治疗真菌感染的方法 |
| WO2021092349A1 (en) * | 2019-11-08 | 2021-05-14 | Scynexis, Inc. | Lipid-based formulations of scy-078 salts |
| CN111658610B (zh) * | 2020-07-31 | 2022-05-24 | 上海方予健康医药科技有限公司 | 一种供雾化器用的三氮唑类抗真菌药物的混悬液 |
| IT202000030443A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Polvere inalabile comprendente voriconazolo in forma cristallina |
| IT202000030437A1 (it) | 2020-12-10 | 2022-06-10 | Zambon Spa | Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo |
| BR112023017538A2 (pt) * | 2021-03-03 | 2023-11-07 | Pulmatrix Operating Co Inc | Formulações de pó seco de di-hidroergotamina e métodos de uso |
| EP4429643A4 (en) * | 2021-11-09 | 2025-11-12 | Agency Science Tech & Res | Salt-based platform antifungal powder formulation for aerosolization |
| US20250049717A1 (en) * | 2021-12-20 | 2025-02-13 | Pulmatrix Operating Company, Inc. | Dry powder formulations of narrow spectrum kinase inhibitors |
| CA3260232A1 (en) | 2022-06-21 | 2023-12-28 | Hovione Scientia Limited | CRYSTALLINE PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING PARTICLES COMPOSITE OF SUGAR AND LIPID AND MANUFACTURING PROCESS |
| WO2024040175A1 (en) | 2022-08-18 | 2024-02-22 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
| JP2025529125A (ja) | 2022-08-31 | 2025-09-04 | パルマトリックス オペレーティング カンパニー，インコーポレイテッド | イトラコナゾール乾燥粉末を使用する方法 |
| WO2025064631A1 (en) * | 2023-09-20 | 2025-03-27 | The Board Of Trustees Of The University Of Illinois | Use of a dry powder inhaler to treat or prevent pulmonary fungal infections |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4097620A (en) | 1977-05-02 | 1978-06-27 | Xerox Corporation | Magnetic toner particle coating process |
| US4916134A (en) | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
| KR100743404B1 (ko) * | 2000-12-21 | 2007-07-30 | 넥타르 테라퓨틱스 | 폴리엔 항균제의 폐 전달 |
| ITMI20010357U1 (it) | 2001-06-28 | 2002-12-30 | Plastiape Spa | Dispositivo inalatore |
| JP2006513235A (ja) | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 真菌感染症療法のためのエアゾール化可能な医薬製剤 |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| JP2007508240A (ja) | 2003-07-22 | 2007-04-05 | バクスター・インターナショナル・インコーポレイテッド | 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法 |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| WO2006026502A1 (en) | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| US20120128728A1 (en) | 2005-12-28 | 2012-05-24 | Novartis Pharma Ag | Compositions Comprising Amphotericin B |
| SG170047A1 (en) * | 2006-05-30 | 2011-04-29 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations |
| MX2009001533A (es) | 2006-08-11 | 2009-02-18 | Panacea Biotec Ltd | Particulas para el suministro de ingredientes activos, procedimiento de elaboracion y sus composiciones. |
| US20110142914A1 (en) | 2007-12-06 | 2011-06-16 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
| AU2009214443B2 (en) | 2008-02-13 | 2013-10-10 | Board Of Regents, The University Of Texas System | Templated open flocs of anisotropic particles for enhanced pulmonary delivery |
| EP2095816A1 (en) | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
| EP2172193A1 (en) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Improved nanoparticulate compositions of poorly soluble compounds |
| CN103200938B (zh) * | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
| CN103857440B (zh) | 2011-06-22 | 2018-09-25 | 维奥姆生物科学有限公司 | 基于缀合物的抗真菌和抗细菌前药 |
| EP2601973A1 (en) * | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
| WO2013132457A2 (en) | 2012-03-07 | 2013-09-12 | National Institute Of Pharmaceutical Education And Research (Niper) | Nanocrystalline solid dispersion compositions and process of preparation thereof |
| WO2014106727A1 (en) | 2013-01-03 | 2014-07-10 | Vectura Limited | Inhaler and formulation |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| AU2014248455B2 (en) * | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| CN104398497B (zh) * | 2014-10-29 | 2017-11-24 | 中山大学 | 伊曲康唑吸入粉雾剂及其制备方法 |
| CN107427650A (zh) * | 2015-01-14 | 2017-12-01 | 瑞必治公司 | 粉末分散方法和装置 |
| WO2018195086A1 (en) | 2017-04-17 | 2018-10-25 | Respira Therapeutics, Inc. | Powder dispersion devices and methods |
-
2017
- 2017-10-13 IL IL265913A patent/IL265913B2/en unknown
- 2017-10-13 AU AU2017341815A patent/AU2017341815B2/en active Active
- 2017-10-13 EP EP17791259.9A patent/EP3525759A1/en active Pending
- 2017-10-13 MX MX2019004322A patent/MX388733B/es unknown
- 2017-10-13 WO PCT/US2017/056497 patent/WO2018071757A1/en not_active Ceased
- 2017-10-13 US US16/341,152 patent/US11116722B2/en active Active
- 2017-10-13 RU RU2019114112A patent/RU2766086C2/ru active
- 2017-10-13 CN CN201780063648.5A patent/CN109996536B/zh active Active
- 2017-10-13 KR KR1020197013649A patent/KR102408798B1/ko active Active
- 2017-10-13 JP JP2019520036A patent/JP7085538B2/ja active Active
- 2017-10-13 NZ NZ752353A patent/NZ752353A/en unknown
- 2017-10-13 CA CA3039485A patent/CA3039485A1/en active Pending
-
2023
- 2023-12-29 US US18/400,054 patent/US20240285523A1/en not_active Abandoned
-
2025
- 2025-02-13 US US19/052,958 patent/US20250221928A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20250221928A1 (en) | 2025-07-10 |
| RU2019114112A (ru) | 2020-11-16 |
| AU2017341815A1 (en) | 2019-05-02 |
| CN109996536B (zh) | 2023-03-07 |
| RU2766086C2 (ru) | 2022-02-07 |
| JP2019534270A (ja) | 2019-11-28 |
| US20200129428A1 (en) | 2020-04-30 |
| MX388733B (es) | 2025-03-20 |
| JP7085538B2 (ja) | 2022-06-16 |
| IL265913B2 (en) | 2024-07-01 |
| KR102408798B1 (ko) | 2022-06-13 |
| CN109996536A (zh) | 2019-07-09 |
| RU2019114112A3 (https=) | 2021-02-12 |
| IL265913A (en) | 2019-06-30 |
| IL265913B1 (en) | 2024-03-01 |
| WO2018071757A1 (en) | 2018-04-19 |
| BR112019007459A2 (pt) | 2019-07-16 |
| KR20190068591A (ko) | 2019-06-18 |
| AU2017341815B2 (en) | 2023-06-15 |
| NZ752353A (en) | 2023-06-30 |
| EP3525759A1 (en) | 2019-08-21 |
| MX2019004322A (es) | 2019-12-11 |
| US20240285523A1 (en) | 2024-08-29 |
| US11116722B2 (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240285523A1 (en) | Antifungal dry powders | |
| JP7549534B2 (ja) | イトラコナゾールを含む肺内投与のための抗真菌配合物 | |
| US20190167579A1 (en) | Itraconazole dry powders | |
| AU2019256453B2 (en) | Methods of treating fungal infections | |
| US20250049717A1 (en) | Dry powder formulations of narrow spectrum kinase inhibitors | |
| US20260048049A1 (en) | Methods for treating cancer using inhaled angiogenesis inhibitor | |
| US20240033218A1 (en) | Dihydroergotamine dry powder formulations and methods of use | |
| NZ793053A (en) | Antifungal dry powders | |
| RU2820457C2 (ru) | Способы лечения грибковых инфекций | |
| BR112019007459B1 (pt) | Pós secos antifúngicos e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250910 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250915 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |